TEG技术 知识与检验科及应用.ppt

* * * * * * * * * * * * * * * * * * * * * * PlateletMapping is a specially designed assay for the TEG analyzer. It measures the effect of anti-platelet agents on platelet function. The assay provides two endpoints: the patient’s maximum platelet function as a reference point and the percentage of inhibition relative to the patient’s reference point. In addition, the PlateletMapping assay identifies resistance or subtherapeutic response to an anti-platelet agent, providing clinicians with the information needed to individualize treatment. * * * * * * * * * * * * * * Understanding how hemostasis is regulated requires an understanding of the balance among three highly interactive primary components. These are: ? The vascular system ? The coagulation proteins ? The platelets For example, changes in the vascular system can influence the function of platelets and coagulation proteins. Understanding the interaction of all the hemostatic components has been demonstrated to be important in the accurate monitoring of hemostasis. Most routine tests such as PT, aPTT, and platelet aggregation monitor the function of isolated components, but not the interaction of these components. In essence, the PT and PTT do not adequately reflect the highly interactive and dynamic coagulation events as they are now understood. Accurate monitoring of hemostasis requires the use of an integrative hemostasis test, which is a test that demonstrates the function of the hemostatic components in the presence of as many as components as possible, such as in whole blood. The TEG? is an example of an integrative hemostasis test. The TEG measures the end result of the complex and dynamic hemostatic process, which is the clot. The TEG demonstrates the rate of clot formation, the strength of the clot, and the stability of the clot. Thus, the TEG demonstrates whether the clot is formed quick enough, if it is strong enough to stop bleeding, and if it is stable enough to provide an opportunity for va